Literature DB >> 19641226

Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks.

Sathyamangla V Naga Prasad1, Zhong-Hui Duan, Manveen K Gupta, Venkata Suresh K Surampudi, Stefano Volinia, George A Calin, Chang-Gong Liu, Ashwin Kotwal, Christine S Moravec, Randall C Starling, Dianne M Perez, Subha Sen, Qingyu Wu, Edward F Plow, Carlo M Croce, Sadashiva Karnik.   

Abstract

It is well established that gene expression patterns are substantially altered in cardiac hypertrophy and heart failure, but the reasons for such differences are not clear. MicroRNAs (miRNAs) are short noncoding RNAs that provide a novel mechanism for gene regulation. The goal of this study was to comprehensively test for alterations in miRNA expression using human heart failure samples with an aim to build signaling pathway networks using predicted targets for the miRNAs and to identify nodal molecules that control these networks. Genome-wide profiling of miRNAs was performed using custom-designed miRNA microarray followed by validation on an independent set of samples. Eight miRNAs are significantly altered in heart failure of which we have identified two novel miRNAs that are yet to be implicated in cardiac pathophysiology. To gain an unbiased global perspective on regulation by altered miRNAs, predicted targets of eight miRNAs were analyzed using the Ingenuity Pathways Analysis network algorithm to build signaling networks and identify nodal molecules. The majority of nodal molecules identified in our analysis are targets of altered miRNAs and are known regulators of cardiovascular signaling. A heart failure gene expression data base was used to analyze changes in expression patterns for these target nodal molecules. Indeed, expression of nodal molecules was altered in heart failure and inversely correlated to miRNA changes validating our analysis. Importantly, using network analysis we have identified a limited number of key functional targets that may regulate expression of the myriad proteins in heart failure and could be potential therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19641226      PMCID: PMC2785678          DOI: 10.1074/jbc.M109.036541

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Signaling pathways for cardiac hypertrophy and failure.

Authors:  J J Hunter; K R Chien
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

2.  Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation.

Authors:  Eric C Lai
Journal:  Nat Genet       Date:  2002-03-18       Impact factor: 38.330

3.  Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes.

Authors:  N H Purcell; G Tang; C Yu; F Mercurio; J A DiDonato; A Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

Review 4.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

5.  The gene expression fingerprint of human heart failure.

Authors:  Fen-Lai Tan; Christine S Moravec; Jianbo Li; Carolyn Apperson-Hansen; Patrick M McCarthy; James B Young; Meredith Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

6.  Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy.

Authors:  S V Naga Prasad; G Esposito; L Mao; W J Koch; H A Rockman
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

7.  Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray.

Authors:  J David Barrans; Paul D Allen; Dimitrios Stamatiou; Victor J Dzau; Choong-Chin Liew
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

8.  Modulation of nuclear factor-kappaB improves cardiac dysfunction associated with cardiopulmonary bypass and deep hypothermic circulatory arrest.

Authors:  Jodie Y Duffy; Kelly M McLean; Jefferson M Lyons; Adam J Czaikowski; Connie J Wagner; Jeffrey M Pearl
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

9.  Expression profiling of human idiopathic dilated cardiomyopathy.

Authors:  Rafal Grzeskowiak; Henning Witt; Mario Drungowski; Rolf Thermann; Steffen Hennig; Andreas Perrot; Karl J Osterziel; Dirk Klingbiel; Stefanie Scheid; Rainer Spang; Hans Lehrach; Patricia Ruiz
Journal:  Cardiovasc Res       Date:  2003-08-01       Impact factor: 10.787

10.  Identification of Drosophila MicroRNA targets.

Authors:  Alexander Stark; Julius Brennecke; Robert B Russell; Stephen M Cohen
Journal:  PLoS Biol       Date:  2003-10-13       Impact factor: 8.029

View more
  57 in total

Review 1.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

Review 2.  Therapeutic potential of microRNAs in heart failure.

Authors:  Gerald W Dorn
Journal:  Curr Cardiol Rep       Date:  2010-05       Impact factor: 2.931

Review 3.  microRNAs in heart disease: putative novel therapeutic targets?

Authors:  Gianluigi Condorelli; Michael V G Latronico; Gerald W Dorn
Journal:  Eur Heart J       Date:  2010-01-29       Impact factor: 29.983

Review 4.  MicroRNAs: redefining mechanisms in cardiac disease.

Authors:  Gerald W Dorn
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

Review 5.  Epigenetic mechanisms underlying cardiac degeneration and regeneration.

Authors:  Pankaj Chaturvedi; Suresh C Tyagi
Journal:  Int J Cardiol       Date:  2014-02-20       Impact factor: 4.164

6.  New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.

Authors:  Kristin M Burns; Barry J Byrne; Bruce D Gelb; Bernhard Kühn; Leslie A Leinwand; Seema Mital; Gail D Pearson; Mark Rodefeld; Joseph W Rossano; Brian L Stauffer; Michael D Taylor; Jeffrey A Towbin; Andrew N Redington
Journal:  Circulation       Date:  2014-07-01       Impact factor: 29.690

Review 7.  Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature.

Authors:  Gerald J Maarman; Rainer Schulz; Karen Sliwa; Ralph Theo Schermuly; Sandrine Lecour
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

8.  Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes.

Authors:  Pia Lindgren Jeppesen; Gitte Lund Christensen; Mikael Schneider; Anne Yaël Nossent; Hasse Brønnum Jensen; Ditte Caroline Andersen; Tilde Eskildsen; Steen Gammeltoft; Jakob Lerche Hansen; Søren Paludan Sheikh
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

9.  NEMO nuances NF-kappaB.

Authors:  Andriy Nemchenko; Joseph A Hill
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

10.  Mouse chromosome 17 candidate modifier genes for thrombosis.

Authors:  Qila Sa; Erika Hart; Joseph H Nadeau; Jane L Hoover-Plow
Journal:  Mamm Genome       Date:  2010-08-11       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.